HELP HealthcareBeta data

Cybin D/B/A Helus Pharma

$9.03+2.61%

Price as of close on Nov 3, 2026 · Financials updated Oct 1, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: Canada
Market cap: 659.7M USD
Enterprise value: 493.4M USD
Full-time employees: 100

Overall health

Not enough data: too little is reported yet for an overall view

Only 2 of 4 categories have enough reported data; an overall score needs at least 3.

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Cybin D/B/A Helus Pharma looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss over the last 12 months.
Cybin D/B/A Helus Pharma reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.
Financials may be out of date. Latest financial period ended 19 months ago.
The latest financial period we have ended 19 months ago, so the scores may not reflect recent results.

StockQuotient Score

—Fundamentals: Yahoo Finance, not primary filings

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-45.0%

Yahoo Finance · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-33.8%

Yahoo Finance · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-21.6%

Yahoo Finance · trailing 12 months · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield43.3%

Yahoo FinanceReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

Insufficient data

Insufficient data: 0 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Profitability

Does it earn well?

Insufficient data

Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

2/3 inputs reported · Partial data

Why

Stronger than most peers on:

▲ Current ratio

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.63

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -0.02Sector median: 0.6250 · MAD: 0.3380

Current ratio10.97×

Yahoo FinanceReported value33% base weight · Z-score 6.05Sector median: 2.5860 · MAD: 1.3850

Debt / equityUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Cybin D/B/A Helus Pharma

Is Cybin D/B/A Helus Pharma getting weaker?: Filing-by-filing changes are tracked only for companies that file with the US SEC.
How is Cybin D/B/A Helus Pharma valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -45.0% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -45.0% vs peers 1.5% (weaker than 100% of peers).
Is Cybin D/B/A Helus Pharma growing?: Insufficient data: 0 of 3 inputs reported (at least 2 needed).
How profitable is Cybin D/B/A Helus Pharma?: Insufficient data: 1 of 3 inputs reported (at least 2 needed).
How risky is Cybin D/B/A Helus Pharma?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 10.97× vs a peer median of 2.59× (stronger than 89% of peers).Current ratio 10.97× vs peers 2.59× (stronger than 89% of peers). A relative measure, not a bankruptcy probability.

Financials

Fiscal years from SEC annual filings · change vs the prior year · amounts in CAD, as reported

Key ratios	FY Mar 2021	FY Mar 2022	FY Mar 2023	FY Mar 2024	FY Mar 2025	Change
Gross margin	23.1%	—	—	—	—	—
Net margin	-3729.2%	—	—	—	—	—
Return on assets (ROA)	-35.0%	-80.5%	-88.1%	-25.9%	-43.7%	▼ 18 pts
Return on equity (ROE)	-37.4%	-88.8%	-98.5%	-26.7%	-47.7%	▼ 21 pts
Free cash flow margin	-2217.8%	—	—	—	—	—
Current ratio	13.57×	7.38×	4.09×	21.65×	7.75×	▼ 64%

HELP price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Cybin D/B/A Helus Pharma looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss over the last 12 months.

Cybin D/B/A Helus Pharma reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Financials may be out of date. Latest financial period ended 19 months ago.

The latest financial period we have ended 19 months ago, so the scores may not reflect recent results.

Questions investors ask about Cybin D/B/A Helus Pharma

Is Cybin D/B/A Helus Pharma getting weaker?

Filing-by-filing changes are tracked only for companies that file with the US SEC.

How is Cybin D/B/A Helus Pharma valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -45.0% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -45.0% vs peers 1.5% (weaker than 100% of peers).

Is Cybin D/B/A Helus Pharma growing?

Insufficient data: 0 of 3 inputs reported (at least 2 needed).

How profitable is Cybin D/B/A Helus Pharma?

Insufficient data: 1 of 3 inputs reported (at least 2 needed).

How risky is Cybin D/B/A Helus Pharma?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 10.97× vs a peer median of 2.59× (stronger than 89% of peers).Current ratio 10.97× vs peers 2.59× (stronger than 89% of peers). A relative measure, not a bankruptcy probability.

Key ratios

FY Mar 2021

FY Mar 2022

FY Mar 2023

FY Mar 2024

FY Mar 2025

Change

Gross margin

23.1%

—

Net margin

-3729.2%

—

Return on assets (ROA)

-35.0%

-80.5%

-88.1%

-25.9%

-43.7%

▼ 18 pts

Return on equity (ROE)

-37.4%

-88.8%

-98.5%

-26.7%

-47.7%

▼ 21 pts

Free cash flow margin

-2217.8%

—

Current ratio

13.57×

7.38×

4.09×

21.65×

7.75×

▼ 64%